论文部分内容阅读
目的 观察辛伐他汀调脂合适剂量及其安全性。方法 16 8例高脂血症病人分为A、B、C、D四组。A组 (无冠心病或糖尿病 ,口服 5～ 10mg/d) 5 4例 ;B组 (冠心病或糖尿病 ,口服 5～ 10mg/d) 30例 ;C组(无冠心病或糖尿病 ,口服 2 0mg/d) 5 4例 ;D组 (冠心病或糖尿病 ,口服 2 0mg/d) 30例 ,比较服药前、服药后 4周、12周血脂等变化。结果 A、B、C、D组降胆固醇均有显效 ,C、D组降甘油三脂亦有显效 ,辛伐他汀对合并或不合并冠心病或糖尿病的病人同样有效。四组的血糖、尿素氮、肌酐、ALT、AST、CK变化差异无显著意义。结论 辛伐他汀调脂疗效肯定 ,小剂量 (5～ 10mg/d)降胆固醇 ,较大剂量 (2 0mg/d)同时降甘油三脂 ,且安全可靠。
Objective To observe the suitable dosage of simvastatin and its safety. Methods 16 cases of hyperlipidemia patients were divided into A, B, C, D four groups. A group (no coronary heart disease or diabetes, oral 5 ~ 10mg / d) 54 cases; B group (coronary heart disease or diabetes, oral 5 ~ 10mg / d) 30 cases; C group (no coronary heart disease or diabetes, oral 20mg / d) 54 cases; group D (coronary heart disease or diabetes, oral 20mg / d) in 30 cases, before taking the drug, 4 weeks after taking the drug, 12 weeks of blood lipids and other changes. Results A, B, C, D cholesterol deprivation were markedly effective, C, D group triglyceride also effective, simvastatin with or without coronary heart disease or diabetes patients as effective. There was no significant difference in the changes of blood glucose, urea nitrogen, creatinine, ALT, AST and CK among the four groups. Conclusions Simvastatin has definite effect on lipid-lowering. Lower doses of cholesterol (5 ~ 10 mg / d) and higher doses of 20 mg / d lower triglycerides and is safe and reliable.